Showing posts with label Dengue. Show all posts
Showing posts with label Dengue. Show all posts

Saturday, April 30, 2016

Philippines - Philippines dengue vaccine update: 200,000 kids vaccinated, 362 adverse events, details on child death

In an update on the first of its kind immunization program with the newly approved dengue vaccine, Dengvaxia, Philippines health officials (DOH) provided the following update Monday.

The Dengue School-Based Immunization program that commenced on Apr. 4 continues on and at the three week mark, a total of 204, 397 (73%) pupils were vaccinated out of 279,393 pupils with parents’ consent.

As of April 24, 2016 a total of 362 cases of Adverse Event Following Immunization (AEFI) from the three regions where the Dengue School Based Immunization Program were received. The top five common reactions were fever, headache, dizziness, vomiting, and rash. The DOH established a strict monitoring and surveillance system for adverse events and side effects following immunization.

There has been a lot of coverage on the fatality of an 11-year-old boy who was vaccinated on Mar. 31.  The DOH offered the following details and explanation of the case:

The patient is claimed to have been diagnosed to have congenital heart disease during his childhood. No maintenance medication was taken since his transfer to his current guardians.  During immunization of dengue vaccine, the patient was screened and assessed by the RHU physician at the school. When asked the guardian (uncle) denied history of fever, illness, and maintenance medication during assessment.

On April 3, 2016 patient developed diarrhea and fever, he was seen and examined the next day at the Bagac Community Medicare Hospital and was diagnosed to have amoebiasis. Patient was sent home with medications. On April 9, the patient was seen and admitted at the Isaac Catalina Medical Center after experiencing difficulty of breathing, fever, and cough. He was initially diagnosed with pneumonia, severe; congenital heart disease in Congestive Heart Failure, and electrolyte imbalance. April 10, the patient was referred and transferred to Bataan General Hospital. April 11, patient had a cardiac arrest and was eventually pronounced dead. The immediate cause of death was pulmonary edema with the following underlying causes: congenital heart disease, Acute Gastroenteritis with moderate dehydration.

The case was presented to the National Adverse Event Following Immunization Committee (NAEFIC) last April 21, 2016 to assess the findings. Their conclusion is consistent with the hospital findings. The dengue vaccination is coincidental. According to NAEFIC, congenital heart disease is not an exclusion criterion for vaccination.

The Philippines reported more than 200,000 dengue cases last year and nearly 600 deaths. As of April 9, 2016, a total of 33, 658 suspected dengue cases were reported nationwide. The Philippines has the highest incidence of dengue and ranks number 1 in the Western Pacific Region from 2013 to 2015.


Monday, July 30, 2012

Philippines - Vaccine offers 5-year immunity versus dengue


Based on the initial results of ongoing local clinical tests, a vaccine developed by a French pharmaceutical company can provide protection against four strains of the deadly dengue virus for five years and without visible side effects.

This was the welcome announcement made Wednesday by an infectious disease specialist who is a member of the clinical trial team.

"Most of the subjects [who were given the complete vaccine or all three doses] have proven to be immune against dengue for five years with no side effect which shows a lot of promise for the vaccine," Dr. Maria Rosario Capeding of the Research Institute for Tropical Medicine (RITM) told the Inquirer.

During Wednesday's forum of the Philippine Pediatrics Society (PPS) Inc., Capeding said that they expected to complete final tests on the vaccine by the end of the year. (See related story on Page A24.)

According to her, of the more than 3,000 subjects in the clinical tests conducted in Manila, close to half received all three doses of the vaccine developed by Sanofi Pasteur Inc. Most of the participants were between the ages of 2 and 45 and residents of the cities of Manila, San Pablo and Cebu.

Capeding described the vaccine as tetravalent or designed to protect against all four dengue virus strains.

During the forum, she also clarified that experts have yet to discover a cure for the deadly illness as she stressed that what was important was for the patient to be immediately brought to a medical facility as soon as symptoms such as fever, headaches, joint pains, stomachaches and vomiting appear.

Capeding, meanwhile, said that experiments were still being conducted on the efficacy of certain plants or herbs, particularly "tawa-tawa," against dengue or other viruses.

"We are trying to determine their potency and the toxins they possess which could have an effect on viruses," she said as she added, "There is still no advisory on the use of tawa-tawa so it is possible that its reported effect of increasing the blood platelet [count] could [just] be a coincidence."

Jeannette I. Andrade
Philippine Daily Inquirer/Asia News Network